Remy Cointreau Q1 Sales Up 105.0% In Organic Terms

French wine and spirits company Remy Cointreau (REMYF.PK) reported that first-quarter sales were 293.1 million euros, up 105.0% in organic terms, driven by continued excellent momentum in the United States and mainland China, and by a clear improvement in the EMEA region.

The Group sales increased by 36.5% at constant currency and scope compared with the first quarter 2019/20 (pre-pandemic).

Quarterly sales rose 95.3% on a reported basis, including a positive scope effect of 0.9% owing to the acquisitions of JR. Brillet and J. de Telmont and an unfavourable currency trend of negative 0.6%.

For 2021/22, Rémy Cointreau remains confident in its ability to outperform the exceptional spirits sector. The Group expects an excellent first half, underpinned by very favourable comparatives and shipment phasing effects as well as new and structurally more buoyant consumption trends in the United States.

Being ahead in the unfolding of its 2030 strategic plan and given the favourable environment, the Group has decided to significantly increase its communication investments.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Mukilteo, Washington-based Ivar's Soup and Sauce Co. is recalling 14,968 sleeves of refrigerated Kettle Classic Clam Chowder With Uncured Bacon citing the possible presence of hard, sharp opaque plastic pieces, the U.S Foof and Drug Administration said. The products were sold exclusively at Costco stores. The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's Cyltezo as the first interchangeable biosimilar to AbbVie's top-selling drug Humira or adalimumab. Cyltezo, originally approved in August 2017, is both biosimilar to, and interchangeable with Humira for Cyltezo's approved uses. The Food and Drug Administration may be planning to allow people to receive Covid-19 vaccine booster shot that is different from the initial dose, reports indicate. The agency is likely to make the announcement on mix and match approach on coronavirus booster vaccines on Wednesday. The move will be part of FDA's expected authorization of boosters for the Moderna and Johnson & Johnson vaccines.
Follow RTT